Cost‐effectiveness of DPYD genotyping prior to fluoropyrimidine‐based treatment for colorectal cancer in Wales

Documenti analoghi

• Health economic considerations for pharmacogenomic services in the United Kingdom: The Centre for Excellence in Regulatory Science and Innovation in Pharmacogenomics
  di: Dyfrig A. Hughes, et al.
  Pubblicazione: (2025)
• DPYD and fluoropyrimidines: Using the data as our guide
  di: Christine M. Walko
  Pubblicazione: (2024)
• Real‐world study on fluoropyrimidine‐related toxicity outcomes in cancer patients with select DPYD variant alleles that received DPYD genotype‐guided dosing
  di: Sofía L. J. Peeters, et al.
  Pubblicazione: (2025)
• Complete DPYD genotyping combined with dihydropyrimidine dehydrogenase phenotyping to prevent fluoropyrimidine toxicity: A retrospective study
  di: Côme De Metz, et al.
  Pubblicazione: (2024)
• Optimizing fluoropyrimidine therapy: Real‐world impact of DPYD genotype‐based dosing on severe toxicity rates
  di: Anouk H. E. van Kan, et al.
  Pubblicazione: (2025)